---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-019026"
form_type: "8-K"
ticker: "ARVN"
cik: "0001655759"
company_name: "ARVINAS, INC."
filed_at: "2026-03-18T23:59:59+00:00"
generated_at: "2026-05-15T09:54:02.670831+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Arvinas reports Phase 1 ARV-102 shows >50% LRRK2 degradation in CSF in Parkinson's patients

## Summary
- ARV-102 achieved approximately 50% or greater LRRK2 reduction in CSF across all doses (20–80 mg) by day 14, maintained through day 28.
- Treatment was well tolerated; all adverse events were mild, with no serious adverse events, discontinuations, or deaths.
- Endolysosomal and neuroinflammatory biomarkers (e.g., CD68, GPNMB) were reduced in cerebrospinal fluid.
- Mean plasma half-life of ARV-102 was 68 hours; CSF exposure increased dose-dependently indicating brain penetration.
- Company plans Phase 1b trial in progressive supranuclear palsy in Q2 2026, with potential registrational trial in late 2026.

## SEC filing metadata
- accession: 0001628280-26-019026
- form_type: 8-K
- ticker: ARVN
- cik: 0001655759
- company_name: ARVINAS, INC.
- filed_at: 2026-03-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1655759/000162828026019026/0001628280-26-019026-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1655759/000162828026019026/arvn-20260318.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-019026
- JSON: https://secwatch.observer/filing/0001628280-26-019026.json
- Plain text: https://secwatch.observer/filing/0001628280-26-019026.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.